-
Mashup Score: 14Donate to Moffitt Cancer Center - 18 hour(s) ago
Cancer touches all of us. Our mission – to contribute to the prevention and cure of cancer – depends on your support. There are many ways you can give to Moffitt and help save lives today.
Source: fundraise.moffitt.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 7Order A Complimentary Moffitt License Plate Today - 5 day(s) ago
Your investment in a Moffitt specialty plate helps researchers develop innovative medicines and treatment protocols-each of which transform lives, one patient at a time.
Source: www.moffitt.orgCategories: General Medicine News, Onc News and JournalsTweet-
Did you know that #Florida has the second-highest cancer burden in America? Your support helps researchers develop innovative medicines and treatment protocols - each of which transform lives, one patient at a time! 💙 Order yours today: https://t.co/nw5RybeVc7 https://t.co/pXOTM6eQxC
-
-
Mashup Score: 5The ReMissions Holiday Album - 6 day(s) ago
The ReMissions brings music and positivity to Tampa and beyond with their first holiday album and all proceeds from the album directly support cancer research at Moffitt.
Source: www.moffitt.orgCategories: General Medicine News, Oncologists1Tweet-
You can bring the sounds of The ReMissions home with their holiday album, available on streaming and limited-edition vinyl. Every purchase supports cancer research. Buy yours now: https://t.co/YhZRc4xetL https://t.co/WdmXHILsUW
-
-
Mashup Score: 28
Speros FL is set to deliver unmatched precision for breast cancer and pediatric patients
Source: www.moffitt.orgCategories: General Medicine News, Oncologists1Tweet-
Scheduled to open in 2026, #SperosFL will transform treatment for left-sided breast cancer and other cancers, including pediatric cases, with the upcoming ProteusONE proton therapy unit. Read more: https://t.co/aNzfhDxriz https://t.co/M7vYuNFIFa
-
-
Mashup Score: 11
Program: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Adult, Epidemiology, Clinical Research, Health outcomes research, Education, Diseases, Real-world evidence, Myeloid Malignancies, Study Population, Human 1 Morsani College of Medicine, University of South Florida, Tampa, FL 2 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 3 Department of Malignant Hematology, H. Lee Moffitt
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Ziad Abuhelwa, MD (@zabuhelwa) discusses a retrospective analysis of the outcomes of a large cohort of MDS patients to compare outcomes between IDH1-MT and wild-type. Read more: https://t.co/pL3aNqTTF8 @ASH_hematology #ASH24 https://t.co/IyebaSFPpl
-
-
Mashup Score: 6Paper: The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma - 12 day(s) ago
Program: Oral and Poster Abstracts Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Research, Adult, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Diseases, Immune mechanism, Biological therapies, Treatment Considerations, Lymphoid Malignancies, Computational biology, Biological Processes, Study Population, Human Praneeth Reddy Sudalagunta, PhD 1 *, David R. Noyes, MS 2 *,
Source: ash.confex.comCategories: General Medicine News, Onc News and JournalsTweet-
Join Praneeth Reddy Sudalagunta, PhD at #ASH24 as he presents the differential effects of bridging therapy on the immune microenvironment and outcomes with idecabtagene-vicleucel in multiple myeloma. Read more: https://t.co/148u07T4t4 @ASH_hematology #MoffittASH24 https://t.co/BIWku7TiPA
-
-
Mashup Score: 9
Program: Oral and Poster Abstracts Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III Hematology Disease Topics & Pathways: Research, Clinical Research, Real-world evidence Abida Babu, MBBS 1, Kathryn Bower, MD 2 *, Madiha Siraj, MD 3 *, Biwei Cao, MS 4 *, Jongphil Kim, PhD 2 *, Hany Elmariah, MD, MS 5, Rawan Faramand, MD 5, Sayeef Mirza, MD, MPH 5, Lia Perez, MD 5 *, Asmita Mishra, MD, MBA 5, Farhad Khimani, MD 5 *, Jose L. Ochoa-Bayona, MD 1 *,
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Join Abida Babu, MBBS as she discusses the effect of fludarabine and melphalan educed-intensity conditioning in comparison to fludarabine and busulfan myeloablative on allogeneic hematopoietic cell transplantation in AML in complete remission. Read more: https://t.co/ZN57Hqmz3w… https://t.co/wQhFMOFsrG https://t.co/bbm0yiAQYb
-
-
Mashup Score: 8Paper: Reprogramming CLL T-Cell Mitochondrial Fitness Using PI3K Inhibition for Enhancing CAR T-Cell Therapy - 12 day(s) ago
Program: Oral and Poster Abstracts Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Fundamental Science, Research, Translational Research, Immunology, Metabolism, Biological Processes, Molecular biology 1 Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 2 Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 3 Department of Experimental Immunology, Amsterdam
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Tomorrow at #ASH24, Wael Gamal, PhD presents on reprogramming chronic lymphocytic leukemia T-cell mitochondrial fitness using PI3K inhibition for enhancing CAR T-cell therapy. Read more: https://t.co/EKeIL0Fd08 @ASH_hematology #MoffittASH24 https://t.co/TIxHXw0SPq
-
-
Mashup Score: 4
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Clinical trials, ALL, Adult, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Adverse Events Bijal D Shah, MD 1, Jeremy Pantin, MD 2 *, Karamjeet S Sandhu, MD 3, Elias Jabbour, MD 4, Jae H. Park, MD 5, Paul Shaughnessy, MD 6, Mehrdad Abedi, MD 7 *, Michael R Bishop, MD 8, Daniel J. DeAngelo, MD, PhD 9, Wolfram Brugger, MD 10 *, Martin
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Bijal Shah, MD discusses the healthcare resource utilization and costs associated with managing CRS and ICANS in patients with relapsed /refractory adult B-cell acute lymphoblastic leukemia receiving obecabtagene autoleucel. Read more 👉https://t.co/yVMHcQ79Fl… https://t.co/RTW8QtbuuB https://t.co/poQq3iWrnp
-
-
Mashup Score: 7
Program: Oral and Poster Abstracts Session: 619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster III Hematology Disease Topics & Pathways: Clinical trials, Research, Clinical Research, Measurable Residual Disease 1 Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 2 Malignant Hematology Department, Moffitt Cancer Center, Tampa, FL 3 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 4
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, David Sallman, MD discusses a prospective evaluation of the impact of measurable residual disease by error corrected next-generation sequencing with CPX-351 in acute myeloid leukemia. Read more: https://t.co/GLeORd6xQR @ASH_hematology #MoffittASH24 https://t.co/3J0NWpxwSL
-
We are all determined to beat cancer, and our team at Moffitt is honored to have your support! In fiscal year 2024, $53.1 million was raised to create the next generation of cancer-fighting treatments. Join us in our fight against cancer by visiting https://t.co/w6FGuhRG1J. https://t.co/3r0haLNF0O